Pediatric Nephrology

, Volume 28, Issue 1, pp 71–76 | Cite as

Spontaneous remission in children with IgA nephropathy

  • Yuko Shima
  • Koichi NakanishiEmail author
  • Taketsugu Hama
  • Hironobu Mukaiyama
  • Hiroko Togawa
  • Mayumi Sako
  • Hiroshi Kaito
  • Kandai Nozu
  • Ryojiro Tanaka
  • Kazumoto Iijima
  • Norishige Yoshikawa
Original Article



Some patients with IgA nephropathy (IgAN) achieve spontaneous remission even when not receiving medication. However, details on such remissions remain unknown. The aim of our study was to clarify this information in the clinical setting of childhood IgAN with minor glomerular abnormalities or focal mesangial proliferation (MGA/FMP).


This study was a retrospective analysis of 96 children with MGA/FMP who did not receive medication from among the 555 patients with newly diagnosed childhood IgAN treated between January 1972 and December 2000. The Kaplan–Meier method and Cox proportional hazard model were used for the analysis.


Of the 96 pediatric patients who did not receive medication, 57 (59.4 %) achieved spontaneous remission. The cumulative spontaneous remission rates among these patients were 57.5  and 77.4 % at 5 and 10 years, respectively, from onset. The mean time from onset to remission was 5.9 ± 0.4 years. Clinical and histological findings were similar between the remission and non-remission groups. Of the 57 patients with spontaneous remissions, ten (17.5 %) also developed a recurrence of urinary abnormalities. The cumulative recurrence-free rates were 79.9 and 67.9 % at 5 and 10 years, respectively, after remission.


The spontaneous remission rate in childhood IgAN with MGA/FMP was higher than expected. Our results suggest that physicians should consider the potential for spontaneous remission and refrain from very aggressive treatment in IgAN patients with MGA/FMP.


Minor glomerular abnormality Focal mesangial proliferation Recurrence Kaplan–Meier method Cox proportional hazard model 



The authors wish to thank all of the participants and attending physicians for their contributions.




  1. 1.
    Appel GB, Waldman M (2006) The IgA nephropathy treatment dilemma. Kidney Int 69:1939–1944PubMedCrossRefGoogle Scholar
  2. 2.
    Barratt J, Feehally J (2006) Treatment of IgA nephropathy. Kidney Int 69:1934–1938PubMedCrossRefGoogle Scholar
  3. 3.
    Yoshikawa N, Tanaka R, Iijima K (2001) Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol 16:446–457PubMedCrossRefGoogle Scholar
  4. 4.
    Yoshikawa N, Ito H, Nakamura H (1992) Prognostic indicators in childhood IgA nephropathy. Nephron 60:60–67PubMedCrossRefGoogle Scholar
  5. 5.
    Yoshikawa N, Ito H, Yoshiara S, Nakahara C, Yoshiya K, Hasegawa O, Matsuo T (1987) Clinical course of IgA nephropathy in children. J Pediatr 110:555–560PubMedCrossRefGoogle Scholar
  6. 6.
    Churg J, Bernstein J, Glassock RJ (1995) Renal disease: Classification and atlas of glomerular diseases, 2nd edn. Igaku-shoin Medical Publishers, Tokyo, pp 86–88Google Scholar
  7. 7.
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMedGoogle Scholar
  8. 8.
    Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS (2003) National Kidney Foundation’s kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111:1416–1421PubMedCrossRefGoogle Scholar
  9. 9.
    Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Grou (2009) Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 24:845–849PubMedCrossRefGoogle Scholar
  10. 10.
    Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N (2008) Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 23:905–912PubMedCrossRefGoogle Scholar
  11. 11.
    Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, Kaito H, Sako M, Iijima K, Yoshikawa N (2012) Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol 27:783–792PubMedCrossRefGoogle Scholar
  12. 12.
    D’Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano DB, Imbasciati E, Ragni A, Bertoli S, Fogazzi G (1986) Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 59:363–378PubMedGoogle Scholar
  13. 13.
    Koyama A, Igarashi M, Kobayashi M (1997) Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research group on progressive renal diseases. Am J Kidney Dis 29:526–532PubMedCrossRefGoogle Scholar
  14. 14.
    Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP (1997) Predictingrenal outcome in IgA nephropathy. J Am Soc Nephrol 8:199–207PubMedGoogle Scholar
  15. 15.
    D’Amico G (2000) Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 36:227–237PubMedCrossRefGoogle Scholar
  16. 16.
    Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS, Pei Y, Cattran DC (2003) A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 18:1541–1548PubMedCrossRefGoogle Scholar
  17. 17.
    Shen P, He L, Li Y, Wang Y, Chan M (2007) Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract 106:c157–c161PubMedCrossRefGoogle Scholar
  18. 18.
    Gutierrez E, Zamora I, Olea T, Alvaro SJ, Bernis C, Praga M (2011) Long-term outcome of biopsy-proven IgA nephropathy presenting with mild proteinuria and or isolated microhematuria. A multicenter study. J Am Soc Nephrol 22:555A, FR-PO1908CrossRefGoogle Scholar

Copyright information

© IPNA 2012

Authors and Affiliations

  • Yuko Shima
    • 1
  • Koichi Nakanishi
    • 1
    Email author
  • Taketsugu Hama
    • 1
  • Hironobu Mukaiyama
    • 1
  • Hiroko Togawa
    • 1
  • Mayumi Sako
    • 2
  • Hiroshi Kaito
    • 3
  • Kandai Nozu
    • 3
  • Ryojiro Tanaka
    • 4
  • Kazumoto Iijima
    • 3
  • Norishige Yoshikawa
    • 1
  1. 1.Department of PediatricsWakayama Medical UniversityWakayama CityJapan
  2. 2.Division for Clinical TrialsNational Center for Child Health and DevelopmentTokyoJapan
  3. 3.Department of PediatricsKobe University Graduate School of MedicineKobeJapan
  4. 4.Department of NephrologyHyogo Prefectural Kobe Children’s HospitalKobeJapan

Personalised recommendations